Reading PEPG? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PEPG free→Reading PEPG? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PEPG free→QuarterlyIQ Insights · PEPG
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 12, 2026, PepGen Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026 and other business updates and issued a press release titled “ PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights .” A copy of the press release is furnished as Exhibit 99.1. The information provided in this Current Report on Form 8-K (this “Form 8-K”), including Exhibit 99.1, shall not be deemed “file…
Results of Operations and Financial Condition. On March 4, 2026, PepGen Inc. (the "Company") announced its financial results for the year ended December 31, 2025 and issued a press release titled "PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights". A copy of the press release is furnished as Exhibit 99.1. The information provided in this Current Report on Form 8-K (this “Form 8-K”), including Exhibit 99.1, shall not be deemed “filed” for purpose…
of this Form 8-K shall be deemed to be furnished and not filed: Exhibit Number Description 99.1 Press release issued by PepGen Inc. on November 12, 2025 104 Cover Page Interactive Data File (embedded within Inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PEPGEN INC. Date: November 12, 2025 By: /s/ Noel Donnelly Noel Donnelly,…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) Repricing of Underwater Options On November 4, 2025, the Board of Directors (the “Board”) of PepGen Inc. (the “Company”) approved an option repricing (the “Repricing”), effective as of November 4, 2025 (the “Effective Date”). The Repricing was undertaken in accordance with, and as permitted by, the Company’s 2020 Stock Plan (the “2020 Plan”), 2…
Entry into a Material Definitive Agreement. On September 24, 2025, PepGen Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated, as joint book-running managers (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of 31,250,000 shares (the “Firm Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”), at a price to the public of…
of this Form 8-K shall be deemed to be furnished and not filed: Exhibit Number Description 99.1 Press release issued by PepGen Inc. on August 7, 2025 104 Cover Page Interactive Data File (embedded within Inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PEPGEN INC. Date: August 7, 2025 By: /s/ Noel Donnelly Noel Donnelly, Chief…
Other Events. On May 28, 2025, the Company announced based on the levels of dystrophin protein measured in the 10 mg/kg cohort of its CONNECT1-EDO51 study investigating PGN-EDO51 in Duchenne muscular dystrophy (“DMD”) patients amenable to exon 51 skipping, the Company will focus on advancing its promising myotonic dystrophy type 1 (“DM1”) program currently in Phase 2 clinical development. The Company is voluntarily discontinuing development of PGN-EDO51 and intends to wind down all DMD-relate…
of this Form 8-K shall be deemed to be furnished and not filed: Exhibit Number Description 99.1 Press release issued by PepGen Inc. on May 8, 2025 104 Cover Page Interactive Data File (embedded within Inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PEPGEN INC. Date: May 8, 2025 By: /s/ Noel Donnelly Noel Donnelly, Chief Financ…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 27, 2025, the Board of Directors (the “Board”) of PepGen Inc. (“PepGen” or the “Company”), on the recommendation of the Nominating and Corporate Governance Committee of the Board, unanimously appointed Mitchell Finer, Ph.D. and Lisa Wyman to fill newly created vacancies on the Board resulting from the expansion of the number of members of…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On March 24, 2025, Michelle L. Mellion, MD resigned from her position as Chief Medical Officer of PepGen Inc. Her resignation will be effective as of the close of business on April 4, 2025. Dr. Mellion’s resignation is not a result of any disagreement with the Company. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 19…
Results of Operations and Financial Condition. On February 24, 2025, PepGen Inc. (the "Company") announced its financial results for the year ended December 31, 2024 and issued a press release titled "PepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights". A copy of the press release is furnished as Exhibit 99.1. The information provided in this Current Report on Form 8-K (this “Form 8-K”), including Exhibit 99.1, shall not be deemed “filed” for pur…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.